Cite
APA Citation
Mok, T., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Yu, C., Thongprasert, S., Sandoval-Tan, J., Lee, J. S., Fuerte, F., Shames, D. S., Klughammer, B., Truman, M., Perez-Moreno, P., & Wu, Y. (2016). tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung cancer, 98, 1–8. http://access.bl.uk/ark:/81055/vdc_100034056922.0x000055